Edition:
United Kingdom

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

12.24USD
7:05pm GMT
Change (% chg)

$0.12 (+0.99%)
Prev Close
$12.12
Open
$12.00
Day's High
$12.27
Day's Low
$11.87
Volume
239,820
Avg. Vol
794,239
52-wk High
$14.47
52-wk Low
$3.30

Latest Key Developments (Source: Significant Developments)

Immunomedics announces first quarter fiscal results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Immunomedics Inc :Immunomedics announces first quarter fiscal 2018 results and provides corporate update.Q1 loss per share $0.97.Q1 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Immunomedics Inc - qtrly ‍total revenue was $0.7 million for both quarters ended September 30, 2017 and September 30, 2016​.  Full Article

Immunomedics reports Q4 loss per share $0.48
Wednesday, 16 Aug 2017 

Aug 16 (Reuters) - Immunomedics Inc :Immunomedics announces fiscal 2017 results and strategic developments; reiterates guidance on bla submission timeline.Q4 revenue fell 33 percent to $600,000.Q4 revenue view $2.3 million -- Thomson Reuters I/B/E/S.Q4 loss per share $0.48.Q4 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Immunomedics Inc - ‍cash, cash equivalents, and marketable securities totaled $154.9 million as of june 30, 2017​.Immunomedics Inc - ‍company expects to present final results of IMMU-132 in mtnbc that will form basis of bla submission later this year​.Immunomedics Inc - ‍believe that current financial resources are sufficient to support operations through september 2018​.  Full Article

Seattle Genetics in licensing deal with Immunomedics
Friday, 10 Feb 2017 

Seattle Genetics Inc : Seattle Genetics announces global license agreement with immunomedics for sacituzumab govitecan (immu-132), a promising late-stage adc for solid tumors . Seattle Genetics Inc - planned bla for triple negative breast cancer indication; other solid tumors being explored in clinic . Seattle Genetics Inc - seattle genetics to lead development, manufacturing and commercialization of sacituzumab govitecan globally . Seattle Genetics inc says seattle genetics is purchasing approximately $15 million of common stock, representing a 2.8 percent stake in immunomedics . Seattle Genetics -upon closing of transactions contemplated by development, license agreement, immunomedics would receive an upfront payment of $250 million . Seattle Genetics Inc - granted right to purchase an additional 8,655,804 shares of common stock at a price of $4.90 per share . Seattle Genetics is purchasing approximately $15 million of common stock, representing a 2.8 percent stake in immunomedics . Seattle Genetics - would pay development, regulatory,sales-dependent milestone payments across multiple indications of up to total maximum of about $1.7 billion . Seattle Genetics Inc - 2017 guidance provided on february 9, does not take into account impact of transactions with immunomedics.  Full Article

Immunomedics announces Q2 fiscal 2017 results and clinical program developments
Thursday, 9 Feb 2017 

Immunomedics Inc : Immunomedics announces second quarter fiscal 2017 results and clinical program developments . Immunomedics Inc says total costs and expenses for quarter ended December 31, 2016 were $15.7 million, compared to $16.4 million for same quarter in fiscal 2016 . Q2 loss per share $0.23 .Q2 revenue fell 43 percent to $400,000.  Full Article

Immunomedics announces novel immuno-oncology program targeting Trop-2-expressing cancers
Monday, 12 Dec 2016 

Immunomedics Inc : Immunomedics announces novel immuno-oncology program targeting Trop-2-expressing cancers . Completing enrollment of 100 TNBC patients into ongoing phase 2 clinical trial of IMMU-132 by year-end 2016 . Immunomedics - submitting a biological license application to FDA for accelerated approval for IMMU-132 for patients with metastatic TNBC in mid-2017 .Immunomedics - presenting interim results of phase 2 clinical trials for patients with urothelial cancer at a symposium on genitourinary cancers to be held in early 2017.  Full Article

Immunomedics reports Q4 loss per share $0.17
Wednesday, 17 Aug 2016 

Immunomedics Inc : Immunomedics announces fiscal 2016 results and clinical program developments . Q4 revenue fell 63 percent to $900,000 . Q4 loss per share $0.17 . Total revenues for Q4 ended June 30, 2016, were $0.9 million, compared to $2.4 million for same quarter last year . Says "We plan to spend approximately $42 million to $44 million during fiscal 2017" .Immunomedics inc says believe current funds are sufficient to continue operations and budgeted research and development programs.  Full Article

Immunomedics says appoints Garone as new CFO
Tuesday, 21 Jun 2016 

Immunomedics Inc : Immunomedics appoints Michael R. Garone as new chief financial officer . Immunomedics Inc says Garone replaces Peter P. Pfreundschuh . Immunomedics Inc says Peter P. Pfreundschuh will serve as a consultant to company for next few months to ensure a smooth transition .Immunomedics appoints Michael R. Garone as new chief financial officer.  Full Article

BRIEF-Immunomedics appoints Michael Pehl president and CEO

* Immunomedics appoints Michael Pehl president and chief executive officer to lead next phase of transformative growth